A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
Ma, Y; Gross, AM; Dombi, E; Pemov, A; Choi, K; Chaney, K; Rhodes, SD; Angus, SP; Sciaky, N; Clapp, DW; et al.
Genetics in Medicine.
2020;
22:1786-1793.
Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST.
Chaney, KE; Perrino, MR; Kershner, LJ; Patel, AV; Wu, J; Choi, K; Rizvi, TA; Dombi, E; Szabo, S; Largaespada, DA; et al.
Cancer Research.
2020;
80:4720-4730.
Brain-wide structural and functional disruption in mice with oligodendrocyte-specific Nf1 deletion is rescued by inhibition of nitric oxide synthase.
Asleh, J; Shofty, B; Cohen, N; Kavushansky, A; Lopez-Juarez, A; Constantini, S; Ratner, N; Kahn, I.
Proceedings of the National Academy of Sciences of USA.
2020;
117:22506-22513.
HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis.
Palomo-Irigoyen, M; Pérez-Andrés, E; Iruarrizaga-Lejarreta, M; Barreira-Manrique, A; Tamayo-Caro, M; Vila-Vecilla, L; Moreno-Cugnon, L; Beitia, N; Medrano, D; Fernández-Ramos, D; et al.
Journal of Clinical Investigation.
2020;
130:3848-3864.
After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation.
Fletcher, JS; Pundavela, J; Ratner, N.
2020;
2:i23-i32.
Distinct Roles for Rac1 in Sertoli Cell Function during Testicular Development and Spermatogenesis.
Heinrich, A; Potter, SJ; Guo, L; Ratner, N; DeFalco, T.
Cell Reports.
2020;
31:107513-107513.
The sixth international RASopathies symposium: Precision medicine—From promise to practice.
Gripp, KW; Schill, L; Schoyer, L; Stronach, B; Bennett, AM; Blaser, S; Brown, A; Burdine, R; Burkitt-Wright, E; Castel, P; et al.
American Journal of Medical Genetics, Part A.
2020;
182:597-606.
NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al.
Acta Neuropathologica.
2020;
139:157-174.
Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.
Guo, J; Chaney, KE; Choi, K; Witek, G; Patel, AV; Xie, H; Lin, D; Whig, K; Xiong, Y; Schultz, DC; et al.
American Journal of Cancer Research.
2020;
10:856-869.
Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone.
Isfort, I; Elges, S; Cyra, M; Berthold, R; Renner, M; Mechtersheimer, G; Aman, P; Larsson, O; Ratner, N; Hafner, S; et al.
Scientific Reports.
2019;
9.